Grand Valley State University’s Technology Commercialization Office (TCO) facilitates the transfer of GVSU innovations to the market.  The University has several innovations available for licensing and commercialization that represent multiple industry sectors.

Available technologies are subject to change depending on ongoing licensing or commercialization deals. For additional information about any of the technologies, please email [email protected], or connect with Linda Chamberlain, [email protected].

SimPull Patient Transfer

This invention addresses the challenges in performing lateral patient transfers specifically.  The device supports making these transfers under the operation of just one clinician, without having to exert any force, or manipulate patients in any way. A qualitative study is currently underway.

Licensed to the Patient Company, January 2020. 

A Novel, Energy-Saving System for Demand-Control Ventilation in Applications of Varying Occupancy

This patent pending invention, when coupled with a demand-control ventilation strategy, provides a state-of-the-art solution to insure an area is neither over nor under ventilated, maintaining a healthy building environment conducive to learning and working. The system has been proven to provide a +20% kWh energy savings, by conditioning only the amount of ventilation air necessary to maintain good indoor air quality and room comfort for users.  

Licensed to Antrum Corporation, July 2020

Sensing Technology

Mutant Nato3 Polypeptides: Manufacture of Dopamine Neurons

PM-Nato3 is a novel polypeptide tool that promises to replace use of costly reagents and simplify the conversion of human stem cells (hSC) into dopamine (DA) neurons. DA neurons are lot in Parkinson's disease (PD) and affected in schizophrenia and other disorders, and therapeutics in the realm represent a growing market of 6.7 billion USD. Products would include cell lines(s) expressing PM-Nato3 polypeptides that have a dopaminergic phenotype to be used for 1) preclinical drug recovery for PD, schizophrenia and other disorders and 2) transplantation into brains of patients with PD. Our technology could be delivered as a lentivirus or cell permeable polypeptide to simplify a time consuming (35 day) and technically difficult process that relies on costly and degradable biological reagents. 
 

Available for License

Endotracheal Tube (ETT) Holder (licensed to Airway Innovations)

Endotracheal tube (ETT) holders currently on the market do not prevent unplanned removal or extubation of a hospital patient’s breathing tube, which can cause significant airway trauma or death. To solve this problem the current invention redesigns the endotracheal tube holder and how an ETT holder interacts with the patient’s face, increasing stability, strength, and comfort, thereby reducing the occurrence of unplanned extubations, pressure sores, and skin breakdown.

In collaboration with Spectrum Health Innovations
Licensed to Airway Innovations, November 2014.

Cough Assist Device

Patients with neuromuscular diseases require a cough assist device to dislodge and remove mucus from their lungs. Therapy consists of bursts of pressure/vacuum or vibration to clear the airway and simulate a cough.  Current solutions are expensive and non-portable.  This invention has delivered a low cost, nonelectric cough assist device with equivalent therapy to the current device.

In collaboration with Beaumont Hospital
Available for License